Analyst Price Targets — HOLX
Page 1 • Showing up to 10
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 21, 2025 10:08 am | — | BNP Paribas | $79.00 | $74.12 | TheFly | Hologic downgraded to Neutral from Outperform at BNP Paribas Exane |
| October 23, 2025 9:49 am | — | Mizuho Securities | $78.00 | $73.93 | TheFly | Hologic downgraded to Neutral from Outperform at Mizuho |
| October 22, 2025 1:31 pm | — | Stephens | $76.00 | $74.01 | TheFly | Hologic downgraded to Equal Weight from Overweight at Stephens |
| October 21, 2025 5:37 pm | — | Leerink Partners | $78.00 | $74.08 | TheFly | Hologic price target raised to $78 from $70 at Leerink |
| October 7, 2025 10:10 am | Vijay Kumar | Evercore ISI | $78.00 | $67.34 | TheFly | Hologic upgraded to Outperform from In Line at Evercore ISI |
| July 31, 2025 11:15 am | — | Mizuho Securities | $75.00 | $64.98 | TheFly | Hologic price target raised to $75 from $70 at Mizuho |
| May 5, 2025 11:25 am | Tejas Savant | Morgan Stanley | $65.00 | $52.73 | TheFly | Hologic price target lowered to $65 from $77 at Morgan Stanley |
| November 5, 2024 11:39 am | Anthony Petrone | Mizuho Securities | $87.00 | $78.80 | StreetInsider | Hologic (HOLX) PT Lowered to $87 at Mizuho |
| October 4, 2024 9:15 am | Anthony Petrone | Mizuho Securities | $90.00 | $79.63 | TheFly | Hologic price target raised to $90 from $85 at Mizuho |
| October 1, 2024 6:01 am | Patrick Donnelly | Citigroup | $85.00 | $81.46 | TheFly | Hologic downgraded to Neutral from Buy at Citi |
×
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for HOLX

Hologic Signs Definitive Agreement to Acquire Reveal Genomics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, a global leader in women's health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast…
Business Wire • Oct 19, 2026
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Bid/Ask/Mark (first):
Core Metrics:
More Greeks (optional):
Valuation:
Price & Momentum:
IV Variants:
IV Units:
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
